<DOC>
	<DOCNO>NCT00121095</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability anti-tumor effect treatment samarium Sm-153 lexidronam combination docetaxel patient castrate metastatic prostate cancer .</brief_summary>
	<brief_title>Study Samarium Sm-153 Lexidronam Combined With Docetaxel Patients With Prostate Cancer</brief_title>
	<detailed_description>The principal objective trial evaluate safety , feasibility , anti-tumor effect novel bone-targeted regimen consist Samarium Sm-153 lexidronam combine docetaxel prednisone . This present study design permit evaluation clinical activity combine two distinct agent show benefit treatment patient advance androgen-independent prostate cancer bone metastases . It enable assessment potential synergistic interaction cytotoxic chemotherapy agent bone-targeting radioisotope agent set bone-targeted therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Samarium ethylenediaminetetramethylenephosphonate</mesh_term>
	<criteria>Have histological evidence adenocarcinoma prostate . Have progressive castrate metastatic disease . Castrate level testosterone ( &lt; 50 ng/ml ) . Treatment maintain castrate level testosterone must continue . Must evidence least 3 bone metastasis bone scan . Patients initial hormone treatment ( exclusive neoadjuvant hormone therapy ) combine androgen blockade approach , must show progression disease follow withdrawal antiandrogen prior enrollment . Patients undergo prior bisphosphonate treatment eligible . Patients receive one prior treatment 153Sm lexidronam 89Sr eligible provide least 12 week treatment 153Sm lexidronam 24 week treatment 89Sr . Life expectancy least 12 week ( base comorbidity ) . KPS &gt; 60 . Lab requirement : White Blood Count ( WBC ) ≥ 3,000/mm3 ; Absolute Neutrophil Count ( ANC ) ≥ 1,500/ mm3 ; Platelet ( PLT ) ≥ 100,000/mm3 ; Hemoglobin ( HGB ) ≥ 10 mg/dl ; Bilirubin ≤ 2.0 mg/dl ; ALT/AST≤ 3 time upper limit normal ; Serum creatinine ≤ 2.0 mg/dl . Patients must sign informed consent . Patients small cell carcinoma . Patients predominant visceral metastasis ( &gt; 3 lung liver lesion ) symptomatic lymphadenopathy ( scrotal pedal edema ) . Patients receive one course external beam radiation therapy direct bone lesion . Clinically significant cardiac disease ( New York Heart Association Class III/IV ) . History malignancy ( nonmelanoma skin cancer ) , unless complete remission therapy disease least five year . Have participate research study protocol clinical trial protocol within 30 day date baseline visit .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>prostate cancer</keyword>
</DOC>